Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, provides an overview of recent trial data concerning the immunotherapy of non-oncogene addicted non-small cell lung cancer (NSCLC). Dr Scagliotti emphasizes the importance of exploring combinations of immunotherapy and other treatment modalities in a clinical setting.
Immunotherapy in NSCLC: a perspective
